SIFI

Aci Sant'Antonio, Italywww.sifigroup.com1expert edge

Italian ophthalmic pharmaceutical company founded 1935, developing and manufacturing specialty eye care treatments across 60+ countries with innovative products for cataracts, glaucoma, infections, and retinopathies.

Why interesting to a deal team

Recently acquired by Faes Farma (2025) for double-digit EBITDA multiple. Strong orphan drug asset (Akantior); demonstrates specialty pharma M&A valuations relevant to deal team assessment.

Experts connected to this company

Israel AkinrinsolaAdvised SIFI shareholders on sale to Faes Farma

Israel Akinrinsola

Managing Director, Healthcare Strategic Advisory

Evercore

BankerLondon

London-based Evercore healthcare banker with a live track record on pharma services, CDMO capacity, and specialty pharma carve-outs across Europe's largest 2019-2024 deals.

Sources

Page titlePress
prnewswire.com/news-releases/sifi-merges-into-faes-farma-to-become-its-ophthalmic-franchise-and-expand-international-access-to-its-portfolio-and-pipeline-302477967.html
No name matchPrimary
sifigroup.com

Strongest evidencePage title2 public sourcesHow the grades work